Compare · AFRM vs CELZ
AFRM vs CELZ
Side-by-side comparison of Affirm Holdings Inc. (AFRM) and Creative Medical Technology Holdings Inc. (CELZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- AFRM operates in Finance, while CELZ operates in Health Care - the two are in different parts of the market.
- AFRM is the larger of the two at $23.08B, about 4904.5x CELZ ($4.7M).
- AFRM has been more active in the news (11 items in the past 4 weeks vs 2 for CELZ).
- AFRM has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Affirm Holdings Inc.
- Creative Medical Technology Holdings Inc.
- Price
- -
- -
- Market cap
- $23.08B
- $4.7M
- 1M return
- -11.75%
- -
- 1Y return
- -10.47%
- -
- Industry
- Finance: Consumer Services
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 1
Affirm Holdings Inc.
Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce in the United States and Canada. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its payments network and partnership with an originating bank, enables consumers to pay for a purchase over time with terms ranging from one to forty-eight months. As of September 30, 2020, the company had approximately 6,500 merchants integrated on its platform covering small businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies. Its merchants represent a range of industries, including sporting goods and outdoors, furniture and homewares, travel, apparel, accessories, consumer electronics, and jewelry. The company was founded in 2012 and is headquartered in San Francisco, California.
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Latest AFRM
- SEC Form 10-Q filed by Affirm Holdings Inc.
- Affirm reports first fiscal quarter 2027 results
- Affirm Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Affirm Holdings Inc.
- SEC Form 4 filed by Chief Accounting Officer Jiyane Siphelele
- Sur la table and Affirm partner to give home cooks more choice in how they pay
- Affirm to participate in upcoming investor conferences
- Monness Crespi & Hardt initiated coverage on Affirm with a new price target
- SEC Form DEFA14A filed by Affirm Holdings Inc.
- SEC Form DEF 14A filed by Affirm Holdings Inc.
Latest CELZ
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
- President & CEO Warbington Timothy was granted 1,000,000 shares (SEC Form 4)
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.